A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...
Consolidating treatment to a single bispecific antibody for DLBCL and follicular lymphoma can improve operational efficiency ...
Clinical Trials Arena on MSN
Incyte reports positive data from tafasitamab phase III trial for DLBCL
Incyte has reported positive top line data from the pivotal Phase III frontMIND trial assessing the safety and efficacy of ...
As the world observes World Lymphoma Awareness Day on September 15th, it 39;s a timely reminder of the ongoing battle against lymphomas, a group of cancers affecting the lymphatic system, especially ...
A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.
The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...
"Histological transformation of FL to DLBCL was a low‐incidence event associated with distinct clinical features and inferior survivals . . . By population‐based analysis and external validation, ...
NORTH CHICAGO, Ill., Sept. 3, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced updated results from the Phase 2 EPCORE ® NHL-6 trial (NCT05451810) evaluating the feasibility of dosing and monitoring ...
"Typically, patients will present with motor weakness, sensory deficits, and pain in nerve sites affected by NL. The most common nerve sites include the cauda equina nerves, the brachial plexus, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback